J. Garcia-Vargas

发表

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.

M. Williams, J. Garcia-Vargas, R. Thomas, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.

A. Santoro, A. Nagler, G. Follows, 2021, Blood advances.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma

B. Childs, Jun Zhu, J. Garcia-Vargas, 2022, Cancer Chemotherapy and Pharmacology.

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

C. Parker, N. James, P. Hoskin, 2012 .

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

S. Fosså, C. Parker, N. James, 2012 .

Preoperative chemoradiation with raltitrexed (tomudex) in T3–4 rectal carcinoma: a phase I-II study

V. Valentini, A. Morganti, C. Rossi, 2002 .

Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.

M. Morris, H. Scher, E. Antonarakis, 2015 .

A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma.

A. Harris, H. Mackay, J. Paul, 2000 .

Qualitative and chronological assessment of toxicities during treatment with raltitrexed (‘Tomudex’) in 861 patients: implications for patient management

J. Garcia-Vargas, T. Sahmoud, S. Green, 1999 .

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.

A. Harris, H. Mackay, J. Paul, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

S. Fosså, D. Bottomley, J. Logue, 2022 .

Development of vorinostat: current applications and future perspectives for cancer therapy.

J. Hardwick, V. Richon, J. Garcia-Vargas, 2009, Cancer letters.

Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

G. Lenz, A. Santoro, A. Nagler, 2018, Blood.

A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

D. Siegel, P. Richardson, C. Mitsiades, 2008 .

Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study.

J. Trédaniel, G. Zalcman, D. Moro-Sibilot, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: Early Clinical Experience

S. Jagannath, D. Siegel, V. Richon, 2008 .

Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib

S. Jagannath, G. Schiller, R. Sobecks, 2008 .

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

C. Parker, N. Vogelzang, J. O’Sullivan, 2013 .

Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases : baseline prognostic factor subgroup analysis

N. James, N. Vogelzang, J. O’Sullivan, 2013 .

Safety and tolerability of vorinostat—Experience from the vorinostat clinical trial program

D. Siegel, J. Wigginton, C. Belani, 2008 .

Vorinostat in solid and hematologic malignancies

E. Galanis, V. Richon, C. Belani, 2009, Journal of hematology & oncology.

A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results

L. Silverman, S. Parmar, H. Kantarjian, 2008 .

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

R. Bernards, H. Kerl, R. Dummer, 2012, Leukemia & lymphoma.

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

G. Lenz, A. Santoro, A. Nagler, 2019, American journal of hematology.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

P. Zinzani, D. Cunningham, G. Verhoef, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

G. Lenz, A. Santoro, A. Nagler, 2017 .

Vorinostat Monotherapy for Solid and Hematologic Malignancies

E. Galanis, V. Richon, C. Belani, 2015 .

Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.

V. Valentini, A. Morganti, B. Barbaro, 2004, International journal of radiation oncology, biology, physics.

A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer

A. Ohtsu, T. Hamaguchi, K. Shirao, 2008 .

Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).

S. Fosså, C. Parker, P. Hoskin, 2012 .

Sten Nilsson, Arne Solberg, Joe M O'Sullivan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies

K. Flaherty, D. Haller, P. O'dwyer, 2004, Cancer Chemotherapy and Pharmacology.

A242 Vorinostat and Bortezomib in Relapsed/Refractory MM

S. Jagannath, D. Siegel, V. Richon, 2009 .

765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL.

M. Morris, H. Scher, E. Antonarakis, 2014, Annals of Oncology.

865 Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

C. Parker, O. Sartor, S. Wilhelm, 2014 .

Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes.

C. Parker, S. Wilhelm, M. Shan, 2013 .

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

J. Kuroda, K. Tobinai, D. Maruyama, 2022, International Journal of Hematology.

Pooled Safety Analysis from Phase I and II Studies for Patients with Relapsed Indolent Non-Hodgkin's Lymphoma Treated with Intravenous Copanlisib

G. Salles, A. Santoro, G. Follows, 2017 .

101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

C. Parker, D. Heinrich, S. Helle, 2013 .

Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases

N. James, S. Nilsson, A. Widmark, 2013 .

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

G. Lenz, A. Santoro, A. Nagler, 2019, Hematological Oncology.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.